-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target

Benzinga·01/06/2026 19:10:29
語音播報
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.